Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial)
Crossref DOI link: https://doi.org/10.1007/s10157-015-1133-z
Published Online: 2015-06-17
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Imai, Enyu
Maruyama, Shoichi
Nangaku, Masaomi
Hirakata, Hideki
Hayashi, Terumasa
Narita, Ichiei
Kono, Hideki
Nakatani, Eiji
Morita, Satoshi
Tsubakihara, Yoshiharu
Akizawa, Tadao
Text and Data Mining valid from 2015-06-17